Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization Martin D. Keltz,

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle Michael W.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Male contraception Fertility and Sterility

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

The normal variabilities of the menstrual cycle

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis Ioannis P. Kosmas, M.D.,

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone M. Yusoff Dawood, M.D.,

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Robert F. Casper, M.D. Fertility and Sterility

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer Mohamed.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Fertility and Sterility

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Presentation transcript:

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh T. Nguyen, M.D., Anthony P. Cheung, M.B., B.S., M.P.H., Peter C.K. Leung, Ph.D. Fertility and Sterility Volume 92, Issue 2, Pages 499-507 (August 2009) DOI: 10.1016/j.fertnstert.2008.06.039 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Estradiol, FSH, and LH concentrations in the flare and luteal protocols during coasting. (A and B) Estradiol. (A) Flare protocol: GnRH agonists (GnRH-a) stop group, n = 9 cycles. GnRH-a were stopped on day -1. GnRH-a continue group, n = 7 cycles. Agonists were continued throughout the coast until the day of hCG or cycle cancellation (day 0). (B) Luteal protocol: GnRH-a stop group, n = 8 cycles. The agonists were stopped on day -1. GnRH-a continue group, n = 35 cycles. Agonists were continued throughout the coast until day 0. In this and subsequent figures, data are shown for the last 4 days of coasting (day -3 to day 0) and are displayed as mean ∀ SEM. Mean values were statistically compared on day -1 and day 0. aP<.05. (C and D) FSH. (C) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (D) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. (E and F) LH. (E) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (F) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. Fertility and Sterility 2009 92, 499-507DOI: (10.1016/j.fertnstert.2008.06.039) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Progesterone, androstenedione (A), and anti-Müllerian hormone (AMH) concentrations in the flare and luteal protocols during coasting. (A and B) Progesterone. (A) Flare protocol: GnRH agonists (GnRH-a) stop group, n = 8 cycles. GnRH-a were stopped on day -1. GnRH-a continue group, n = 4 cycles. The agonists were continued throughout the coast until the day of hCG administration or cycle cancellation (day 0). (B) Luteal protocol: GnRH-a stop group, n = 7 cycles. The agonists were stopped on day -1. GnRH-a continue group, n = 9 cycles, Agonists were continued throughout the coast until day 0. In this and subsequent figures, data are shown for the last 4 days of coasting (day -3 to day 0) and are displayed as mean ∀ SEM. Mean values were statistically compared on day -1 and day 0. aP<.05. (C and D) Androstenedione. (C) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (D) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. (E and F) AMH. (E) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (F) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. Fertility and Sterility 2009 92, 499-507DOI: (10.1016/j.fertnstert.2008.06.039) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions